Table 2.

The effect of used compounds and procedures on the locomotor activity of mice.

	Treatment mg/kg	Locomotor activity (% of control)
A.	Control Lanicemine 2 Lanicemine 2 + Hyperforin 1 Lanicemine 10 Lanicemine 10 + Hyperforin 5	100.0 ± 5.46 105.1 ± 9.16 129.2 ± 13.88 87.77 ± 4.70 82.8 ± 12.96
B.	Control MK-801 MK-801 + Hyperforin	100.0 ± 4.89 123.8 ± 15.24 76.44 ± 12.29#
C.	Control Hyperforin 2.5 Lanicemine Fluoxetine Lanicemine + Hyperforin CORT CORT + Hyperforin CORT + Lanicemine CORT + Fluoxetine CORT + Lanicemine+Hyperforin	100.0 ± 7.21 91.74 ± 8.12 131.1 ± 13.97 104.2 ± 7.87 90.74 ± 12.2 122.9 ±6.45 90.88 ±9.60 130.2 ± 15.71 97.94 ± 2.35 101.6 ± 11.69
D.	Control Hyperforin 5 NMDA 75 NMDA 75 + Hyperforin 5 MK 2206 MK 2206 20 + Hyperforin 5	100.0 ± 3.16 55.83 ± 5.72** 69.25 ± 8.00* 57.01 ± 11.45** 82.99 ± 6.98 73.4 ± 6.67*
E.	Control Larixyl acetate 10nmol/2ul Hyperforin 2.5 Larixyl acetate 10nmol/2ul + Hyperforin 2.5	100.0 ± 9.60 84.5 ± 9.51 87.97 ± 21.6 40.31 ± 10.81*

Locomotor activity was measured immediately after TST.

^*p < 0.05;

^**p < 0.01 vs. Control;

^#p < 0.05 vs. MK-801. Data was analyzed by one way ANOVA (A–D) or two way ANOVA and Newman-Keuls multiple comparisons test. All values are expressed as mean ± S.E.M. (A) F_{(4, 20)} = 3.719; p = 0.02; (B) F_{(2, 12)} = 4.191; p = 0.04; (C) [CORT: F_{(1, 47)} = 0.659; p = 0.421; Treatment F_{(4, 47)} = 4.476; p = 0.004; Interaction F_{(4, 47)} = 0.716; p = 0.585]. (D) F_{(5, 28)} = 5.668; p = 0.001; (E) F_{(3, 13)} = 3.766; p = 0.038. n = 4–6.